Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Daily News

Platelet Hyperreactivity Score May Improve CVD Risk Detection

L.A. McKeown

August 23, 2024

News Daily News

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

L.A. McKeown

July 24, 2024

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

L.A. McKeown

November 24, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Daily News

Readmission for Critical Limb Ischemia Common and Largely Unplanned

L.A. McKeown

April 10, 2017

News Daily News

More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions

L.A. McKeown

October 26, 2015

Advertisement

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

Platelet Hyperreactivity Score May Improve CVD Risk Detection

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

Worse Complications After PVI in Women Highlight Research Gaps

High Lp(a) May Predict Risk of CV and Limb Events in PAD

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Readmission for Critical Limb Ischemia Common and Largely Unplanned

More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content